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Abstract
Background: Mitochondrial dysfunction was reported in schizophrenia, bipolar disorderand major depression. The present
study investigated whether mitochondrial complex I abnormalities show disease-specific characteristics.
Methodology/Principal Findings: mRNA and protein levels of complex I subunits NDUFV1, NDUFV2 and NADUFS1, were
assessed in striatal and lateral cerebellar hemisphere postmortem specimens and analyzed together with our previous data
from prefrontal and parieto-occipital cortices specimens of patients with schizophrenia, bipolar disorder, major depression
and healthy subjects. A disease-specific anatomical pattern in complex I subunits alterations was found. Schizophrenia-
specific reductions were observed in the prefrontal cortex and in the striatum. The depressed group showed consistent
reductions in all three subunits in the cerebellum. The bipolar group, however, showed increased expression in the parieto-
occipital cortex, similar to those observed in schizophrenia, and reductions in the cerebellum, yet less consistent than the
depressed group.
Conclusions/Significance: These results suggest that the neuroanatomical pattern of complex I pathology parallels the
diversity and similarities in clinical symptoms of these mental disorders.
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Introduction
The past decade has witnessed an abundance of studies focusing
on mitochondrial abnormalities in several mental disorders
including schizophrenia, bipolar disorder and major depression.
The role mitochondria play in mental disorders has been
investigated using a wide array of experimental techniques ranging
from imaging studies through ultrastructural methods to genetic
and molecular means.
Imaging studies using phosphorous magnetic resonance spec-
troscopy (
31P-MRS) and
1H- MRS demonstrated reduced
mitochondrial originated high energy phosphates, such as ATP
and phosphocreatine (PCr) as well as other cellular factors whose
metabolism is strongly suggested to be linked to mitochondrial
ATP production, in schizophrenia relevant brain structures of
schizophrenic patients [1–8]. In bipolar disorder similar mito-
chondrial abnormalities have been reported [9–11], while in major
depression, the current literature on MRS studies is sparse and
inconsistent [12–14].
Genetic studies also implicate mitochondria abnormalities in
schizophrenia and in affective disorders. For example, two single
nucleotide polymorphisms (SNPs) in a nuclear encoded subunit of
complex I, NDUFV2, were found to be associated with
schizophrenia and with bipolar disorder [15,16]. Additional
genetic variations in mitochondrial DNA encoded ND3 and
ND4 subunits of complex I were associated with bipolar disorder
and schizophrenia, respectively [17,18]. These studies suggest the
genetic variation in complex I as a risk factor in both disorders.
Finally, accumulating molecular, transcriptomic, proteomic and
metabolomic approaches as well as biochemical data points to
abnormalities in mitochondria in both periphery and brain in
schizophrenia [19–28]. Focusing on the mitochondrial oxidative
phosphorylation system (OXPHOS) in schizophrenia, revealed
alterations in the enzymatic activities of complexes IV, II and I–III
and in mRNA and protein levels of complex I subunits, NDUFV1
and NDUFV2, in post-mortem brain specimens [26,29–32].
Similarly, alterations both in complex I activity and its subunit
expression were observed in peripheral blood cells of schizophren-
ic patients [22,27,33,34]. In bipolar disorder a reduction in the
expression level of mitochondrial genes, including those of the
OXPHOS was observed in hippocampal and prefrontal postmor-
tem specimens [35–37], while an increase in complex I subunits
NDUFV1 and NDUFV2 was observed in the parieto-occipital
cortex [26]. In major depression, although most studies did not
show cortical modifications in mitochondrial related genes, some
reports suggest alterations in the expression of nuclear as well as in
mitochondrial DNA encoded genes in the prefrontal cortex
[26,37]. In addition, it was demonstrated that muscle mitochon-
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of the OXPHOS complexes I+III and II+III was impaired [38].
The studies described hitherto suggest a dysregulation of
mitochondrial function in schizophrenia and mood disorders,
consequently raising the question as to whether mitochondrial
impairment displays disease-specific characteristics or is rather a
general non-distinguishing pathology of these disorders. Complex
I, the focus of the present study, plays a major role in controlling
oxidative phosphorylation, and therefore mitochondrial function
[39]. The aim of the present study was to determine whether
complex I abnormalities show disease-specific characteristics.
mRNA and protein levels of three subunits of complex I,
NDUFV1, NDUFV2 and NDUFS1, all forming one functional
subunit, were assessed in postmortem brain specimens of striatum
and cerebellum of patients with schizophrenia, bipolar disorder or
major depression and normal subjects, and analyzed together with
our previous data from prefrontal and parieto-occipital cortices of
the same cohorts. Tables 1, 2, 3 summarize the main clinical,
functional, biochemical and pathogenic characteristics of the
different mental disorders, brain areas and complex I subunits
investigated in the present study. The abnormality in mitochon-
drial complex I subunits’ parameters demonstrated disease-specific
regional distribution discriminating between schizophrenia, bipo-
lar disorders and major depression.
Materials and Methods
Post-mortem tissues
Frozen samples from the striatum including the nucleus
accumbens, and the lateral cerebellar hemisphere, were provided
by the Stanley Foundation Neuropathology Consortium (Bethesda,
MD). Samples were obtained from individuals diagnosed (DSM-IV
criteria) with schizophrenia, bipolar disorder or major depression
and normal controls 15 subjects in each group. Medication
undertaken by each patient is summarized in Table 4. The four
groups are matched by age, sex, race, postmortem interval (PMI),
pH, laterality, and mRNA quality. Demographics are presented in
Table 5.A moredetailed description of theStanleyBrain Collection,
and protection of human rights is reported in [40]. All 60 samples
were analyzed in parallel, blind to patients’ diagnosis.
RT-PCR
RNA was extracted from tissue using RNA STAT-60 kit (TEL-
TEST, INC, Frienwood, TX,) and treated by DNase as described
previously [27,41]. RNA integrity depicted in the form of three
bands corresponding to 28S, 18S and 5S-RNA was assessed by
electrophoresis, and its amount and purity was determined
spectophotometricaly. The expression of NDUFV1, NDUFV2 and
NDUFS1 encoding for 51-kDa, 24-kDa and 75-kDa subunits of
complex I, respectively, was studied by reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis. Amplification of
RT-cDNA was first performed on a control specimen at different
concentrations to define a linear range for all genes. Number of
cycles, cDNA amount and primers concentration were established
according to a stringent calibration process determining the log-
linear phase of amplification for each gene. After establishing the
optimal reaction conditions, amplification was performed at least
twice for each individual. Sequences of PCR primers for NDUFV1,
NDUFV2, NDUFS1, 18S-RNA and b-actin are summarized in
Table 6. b-actin and 18S-RNA were used for assessment of RNA
quality and yield. b-actin and 18S-RNA were used for assessment
of RNA quality and yield. The b-actin was used for normalizing
variations in RNA aliquots, as its levels were not affected by
disease. A single batch of human platelets RNA, on which PCR
was performed at three different concentrations, was assayed in
parallel with each set of samples as a positive control, to control for
the log-linear phase of amplification for each reaction and for
between sample-sets normalization.
Table 1. Clinical characteristics of the three different mental disorders investigated in the present study.
Disease
Population
prevalence
Typical age
of onset
Gender
differences
Symptoms according to the Diagnostic and statistical Manual of Mental
Disorders –DSM-IV
Schizophrenia 1.1%
a M – 18 yr
F – 25 yr
F=M The essential features of Schizophrenia are a mixture of characteristic signs and
symptoms (both positive and negative) that have been presented for a significant
portion of time during a 1 month period with some signs persisting for at least 6
months. These signs include cognitive, emotional and behavioral anomalies.
Positive symptoms: delusions, hallucinations, disorganized speech (eg. frequent
derailment or incoherence), grossly disorganized or catatonic behavior, Negative
symptoms, i.e. affective flattening, alogia or avolition.
Two or more of these symptoms each present
Bipolar disorder (BP) 2.6%
a 20–35 yr F=M The essential feature of BP is the occurrence of one or more Manic episodes. Often
individuals have on or more MD episodes whose symptoms are summarized for MD.
Manic episode: inflated self-esteem or grandiosity, decreased need for sleep, flight of
ideas, distractibility, increase in goal-directed activity or psychomotor agitation,
excessive involvement in pleasure activitiesthat have high potential of painful
consequences.
Three or more of these symptoms lasting for at least 1 week.
Major depression (MD) 5.3%
a 30–40 yr with
wide variations
F.M The essential feature of MD is a period of at least 2-weeks during which there is either
depressed mood or lost of interest or pleasure in nearly all activities.
Five or more of the following symptoms presented during 2-weeks and represent
change from previous functioning: Depressed mood, markedly diminished interest or
pleasure, significant weight loss or weight gain, insomnia or hypersomnia,
psychomotor agitation or retardation, fatigue or loss of energy, felling worthless or
excessive inappropriate guilt, diminished ability to think or concentrate, recurrent
thoughts of death.
doi:10.1371/journal.pone.0003676.t001
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Protein isolated from frozen specimens was analyzed by
immunoblotting three times for each individual [26]. Protein
samples were separated on SDS-PAGE. Primary customized
recombinant rabbit antihuman antibodies used; anti-51-kDa
1:500, anti-24-kDa 1:1500, anti-75-kDa 1:1000 synthesized by
Sigma-Aldrich, Israel. Secondary antibodies used; anti rabbit-IgG
1:15,000 for 24-kDa, and 1:10,000 for 51-k-Da and 75-kDa
subunits (Santa Cruz Biotechnology Santa Cruz, CA). b-actin was
used for normalizing variations in protein aliquots, as its levels
were not affected by disease. In addition, a single batch of rat brain
mitochondrial protein in three different concentrations was used as
a positive control and for between sample-sets normalization.
Statistical analysis
Normal distribution of data was analyzed by Kolmogorov-
Smirnov test. For further analysis parametric tests were used, as
most data (90%) presented normal distribution. For data not
distributed normally, non-parametric and parametric tests
showed similar differences between groups. Data were analyzed
by two-way ANOVA followed by Bonferroni post-hoc test. Age,
gender, laterality, PMI, brain pH, disease duration, drug and
alcohol abuse and medication were added as covariates and
persistence of the significant difference in main effect between
diagnostic groups was assessed by ANCOVA. Correlations were
analyzed by Pearson correlation test. SPSS version 14.0 software
was used.
Table 2. Functional characteristics of the four different brain areas investigated in the present study.
Brain area sections Location Function Reference:
Striatum including
the nucleus accumbens
Caudate: motor control, learning and memory (especially feedback processing), language
comprehension
[91–98]
Putamen: reinforcement learning
Nucleus accumbens: reward, addiction and emotions such as pleasure and laughter, fear,
and the placebo effect.
Cerebellum Balance, coordination, muscle tension, posture, balance of limbs, fine motion control and
eye movement. Recent findings suggest a role in mood and cognition (70)
[99–102]
BA 46/9 Dorsolateral prefrontal
cortex
Motor planning, organization, and regulation. It plays an important role in the integration
of sensory and mnemonic information and the regulation of intellectual function and action
and working memory.
[103–106]
BA 19 Extrastriate cortex in the
occipital cortex
A visual association area, with feature-extracting, shape recognition, attentional, and
multimodal integrating functions
[107–109]
doi:10.1371/journal.pone.0003676.t002
Table 3. Biochemical and pathogenic characteristics of complex I subunits investigated in the present study.
Complex I
subunit Biochemical function Pathology associated with mutations or polymorhism
NDUFV1 Flavoprotein, contains the NADH-binding site, and binds NADH
released electron together with NADUV2.
Leigh-Like syndrome with early onset Ophthalmoplegia (611ARG (Y204C))/ 616TRG
(C206G) [112]
Catalytic sites: Mitochondrial Complex I Deficiency - 611ARG (Y204C); 616TRG (C206G); 640GRA
(E214K);1294GRC (A432P) ; Deletion nt 989–990 [113]
flavin mono-nucleotide (FMN) Leukodystrophy and myoclonic epilepsy 175CRT (R59X); 1268CRT (T423M) [114]
4Fe-4S cluster (N3) [110,111]
NDUFV2 Flavoprotein that together with NDUFV1 binds the electron
and passes it probably to NDUFS1 Catalytic sites:
Schizophrenia – polymorphisms – rs56506640 (23542A.G); rs 51156044
(2602GRA) [115]
2Fe-2S cluster (N1a)[110,111] Bipolar disorder – polymorphisms- rs56506640 (23542A.G); rs 51156044
(2602GRA) [115,116]
Early onset hypertrophic cardiomyopathy and encephalopathy- 4-bp deletion- IVS2
+5-+8 (GTTA) [117]
Parkinson’s disease Parkinson’s disease – polymorphism (182CRT) [118]
NDUFS1 Iron sulfur protein. The largest transmembrane subunit of
complex I.
Mitochondrial Complex I Deficiency –721CR T (R241W); 755 ARG (D252G); 2119
ARG (M707V);664–666 3 bp deletion 222 [113]
Catalytic sites:
2Fe-2S cluster (N1b)
4Fe-4S cluster (N4)
and probably 4Fe-4S cluster (N5) [110,111]
doi:10.1371/journal.pone.0003676.t003
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Protein and mRNA levels of complex I subunits, 51-, 24- and 75-
kDa, were analyzed in two brain specimens obtained from the
striatum and the lateral cerebellarhemisphere(Fig1) of patients with
schizophrenia, bipolar disorder, major depression and normal
subjects. In a previous study we have shown alterations in the same
three subunits, in specimens obtained from the prefrontal (BA9/46)
and the parieto-occipital (BA19) cortices of the same subject cohorts
[26]. Results of the two studies were combined and analyzed by two-
Table 4. Summary of medication undertaken by each patient in each diagnostic group.
Psychiatric diagnosis
Schizophrenia Bipolar Major depression
Subject #
1 Thiothixene, desipramine Thiothixene, carbamazepine, lithium, trazadone Imipramine, amitriptyline, nortiptyline, clonazepam
2 None; untreated for over 20 yrs. Valproate, sertraline, chlorprothixene,
carbamazepine
Lithium
3 None; untreated for several months Lithium, bupropion, clonazepam, lorazepam Fluoxetine, imipramine, lorazepam
4 None; had ECT but probably never treated otherwise Lithium, carbamazepine Phenytion for a single seizure; no other meds for
5 yrs
5 Thioridazine, amitriptyline Lithium, clozapine No medication for 6 yrs
6 Clozapine Never treated Diphenhydramine, cloxazepam
7 Clozapine Haloperidol, diphenhydramine Fluoxetine, lithium
8 Haloperidol, iphenhydramine Risperidone, valproate, venlafaxine Nefazadone, hydroxyzine
9 Risperidone, paroxetine Untreated for over 20 years Never treated
10 Haloperidol, carbamazepine, fluoxetine, clonazepam,
benzotropine
Halperidol, trazadone, trihexphenidyl Temazepam but off medications for more than 2
months
11 Clozapine, chlorpromazine, lithium Valproate, bupriopion Sertraline
12 Haloperidol, lithium, diphenhydramine, chloral hydrate None, untreated for several months Venlafaxine, buspirone, alprazolam
13 Clozapine, chlorpromazine, maprotiline, benzotropine,
diphenhydramine
Fluoxetine, valproate None
14 Haloperidol, clozapine, clonazepam Valproate, clozapine, flurazepam, benzotropine Trimipramine
15 Risperidone,thioridazine Valproate, clomipramine Fluoxetine, nefazadone
doi:10.1371/journal.pone.0003676.t004
Table 5. Demographic data for post mortem brains.
Variable
Control
(n=15)
Schizophrenia
(n=15)
Bipolar disorder
(n=15)
Major depression
(n=15)
Age (years, means6S.D.) 48.1610.7 44.53613.11 42.3611.7 46.469.3
Gender (male, female) 9M, 6F 9M, 6F 9M, 6F 9M, 6F
Postmortem interval (h, means6S.D.) 23.769.94 33.94614.62 32.5616.1 27.5610.7
Cause of death
Cardiac 13 6 4 7
Accident 22 1
Suicide 49 7
Other 31 1
Age of onset (years, means6S.D.) N/A 23.2067.95 33.93613.29 21.4768.35
pH (means6S.D.) 6.360.2 6.260.26 6.260.2 6.260.2
Brain hemisphere used (right:left) 8:7 9:6 7:8 9:6
Lifetime antipsychotic dose
a (mg, means6S.D.) 0 52267662061 20827624016 0
History of psychosis 15 11 with
4 without
Current alcohol/drug abuse or dependence 0 3 4 3
Past alcohol/drug abuse or dependence 2 3 3 1
aLifetime antipsychotic dose in fluphenazine milligram equivalents. N/A – not applicable.
doi:10.1371/journal.pone.0003676.t005
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two independent variables and mRNA and protein levels of 51-, 24-
and 75-kDa as the dependent variables. The 75-kDa subunit was
assessed in three brain regions, as parieto-occiptal cortex specimen
was insufficient. A highly significant interaction between disease
cohorts and brain areas for all dependent variables was observed
Table 6. Primer sequences and PCR conditions.
mRNA primer sequence
Denaturing
temperature and
time uC (s)
Annealing
temperature and
time uC (s)
Elongation
temperature and
time uC (s)
Number of
cycles
Product
size (bp)
NDFUV1 S5 9-TACATCCGAGGGGAATTCTACA-39 94 (60) 60 (60) 72 (60) 35 426
NS 59-GTTCTTTCAAGGGCACAGACAT-39
NDUFV2 S5 9-GGAGGAGCTTTATTTGTGCAC-39 94 (60) 55 (60) 72 (60) 35 640
NS 59-CCTGCTTGTACACCAAATCC-39
NDUFS1 S5 9- TACTCGCTGCATCAGGTTTG-39 94 (60) 58 (60) 72 (60) 35 299
NS 59-CATGCATACGTGGCAAAATC-39
b-actin S 59-TGAAGTGTGACGTGGACATCCG-39 94 (60) 60 (60) 72 (60) 25 447
NS 59-GCTGTCACCTTCACCGTTCCAG-39
18S-RNA S 59-AGGAATTGACGGAAGGGCAC-39 94 (60) 60 (60) 72 (60) 25 324
NS 59-GTGCAGCCC CGGACATCTAAG-39
doi:10.1371/journal.pone.0003676.t006
Figure 1. Diagrams of brain section presenting the four different brain areas in which complex I subunits were assessed. A) The
prefrontal cortex (BA 9/46) sections are 14 mm frozen coronal sections though the area marked in blue B) The striatum sections are 14 mm frozen
coronal sections through the head of the caudate nucleus and putamen at the level of the nucleus accumbens. C) The parieto-occipital cortex (BA 19)
sections are 14 mm frozen coronal sections though the area marked in blue. D) The cerebellar sections are 14 um frozen sagittal sections through the
lateral cerebellar hemisphere at the level marked by the green line. Diagram are obtained from the Atlas of the Human Brain by Jurgen K. Mai, Joseph
Assheuer and George Paxinos, 1997 3
rd Ed. pp. 123, 124, 126 Elsevier Ltd.
doi:10.1371/journal.pone.0003676.g001
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affect complex I subunits expression in various brain areas.
Alterations in complex I subunits in the prefrontal and the
parieto-occipital cortices which were previously discussed [26] and
are presented in Table 8. Data of complex I subunits’ expression in
the striatum and the cerebellum are further analyzed for disease
related effects.
Complex I subunits in the striatum
The significant difference in mRNA levels between the four
subject cohorts for each subunit of complex I (NDUFV1-
F(3,56)=5.838, p=0.002; NDUFV2-F(3,56)=3.781, p=0.015;
NDUFS1-F(3,56)=10.155, p=0.0001) was due to a significant
decrease in levels of NDUFV1 (41%; p=0.003), NDUFV2 (46%;
p=0.0001),and NDUFS1 (60%; p=0.0001) in the schizophrenic
group as compared to controls. The bipolar and depressed groups
did not differ from the controls. Interestingly, the schizophrenic
group differed significantly from both mood disorder groups
(NDUFV1, p=0.004 vs. bipolar; NDUFV2, p=0.03 vs. de-
pressed; NDUFS1, p=0.009 and p=0.000 vs. bipolar and
depressed, respectively). However, no difference was observed
between depressed and bipolar patients (Fig 2).
Protein levels of the 51-kDa (NDUFV1) and 24-kDa (NDUFV2)
subunits, but not of 75-kDa (NDUFS1), showed a parallel pattern of
change to that of the mRNA, throughout the four cohorts (F(3,56)=
5.604, p=0.002, F(3,56)=6.704, p=0.001 and F(3,56)=6.067,
p=0.001, respectively) (Fig 3). Thus, a significant decrease of 51-
kDa (31%; p=0.040) and 24-kDa (30%; p=0.045) subunits, was
observed in the schizophrenic group. While the depressed group did
not differ from the controls for all three subunits, the bipolar group
showed a slight, yet significant,decrease inthe75-kDa subunit(17%;
p=0.045). Similar to the findings in mRNA, the schizophrenic
group differed significantly from both mood disorder groups (51-
kDa, p=0.002 vs. depressed; 24-kDa, p=0.001 vs. bipolar; 75-kDa,
Table 7. Two way ANOVA results of disease and brain area
dependent alterations in complex I subunits.
Dependent Variable df F Sig.
Cohort NDUFV1 3 8.131 0.000
NDUFV2 3 11.297 0.000
NDUFS1 3 9.646 0.000
51-kDa 3 3.513 0.020
24-kDa 3 5.663 0.001
75-kDa 3 6.935 0.000
Area NDUFV1 3 43.306 0.000
NDUFV2 3 152.980 0.000
NDUFS1 2 16.815 0.000
51-kDa 3 368.109 0.000
24-kDa 3 432.844 0.000
75-kDa 2 399.590 0.000
Cohort*Area NDUFV1 9 2.795 0.004
NDUFV2 9 9.008 0.000
NDUFS1 6 4.773 0.000
51-kDa 9 7.148 0.000
24-kDa 9 7.819 0.000
75-kDa 6 4.295 0.000
The NDUFV1, NDUFV2 and NDUFS1 and 24-, 51- and 75-kDa stand for mRNA
and protein levels of the three subunits of complex I, respectively. All subunits
were analyzed in 4 brain areas, the striatum, the lateral hemisphere of the
cerebellum, the prefrontal cortex (BA9/46) and the parieto-occipital cortex
(BA19) in schizophrenia, bipolar disorder and major depression and normal
subjects. The 75-kDa subunit was analyzed in all brain areas except the parieto-
occipital cortex (BA19).
doi:10.1371/journal.pone.0003676.t007
Table 8. Summary of mRNA and protein levels in four different brain areas.
Striatum Cerebellum Prefrontal cortex (BA 46/9) Parieto-occipital cortex (BA 19)
NDUFV1 (51 kDa)
mRNA protein mRNA protein mRNA protein mRNA protein
Normal 1.8360.51 1.7860.37 1.2560.27 1.6360.32 1.4360.68 0.8060.21 0.3760.14 1.6660.30
SCH 1.0960.26 * 1.3560.24 * 1.2860.3 1.2560.60 0.8360.16 * 0.6660.31 * 0.5960.44* 1.9260.17 *
MD 1.5260.46 1.9560.34 1.0060.31 * 0.8360.24 * 1.0260.50 0.7760.40 0.2860.35* 1.7360.28
BP 1.8160.84 1.5360.68 0.8860.24 * 0.9260.22 * 1.4961.20 0.7660.32 0.4060.23 2.2460.63 *
NDUFV2 (24-kDa)
mRNA protein mRNA protein mRNA protein mRNA protein
Normal 1.2460.32 1.0360.22 1.5960.48 1.0460.17 0.5060.07 0.8960.24 0.3160.17 1.3560.18
SCH 0.6760.18* 0.7360.12 * 1.3460.64 1.0660.45 0.3460.09* 0.3960.19 * 0.6660.37* 1.9260.36 *
MD 1.2360.81 0.9360.19 0.8560.30 * 0.5760.22 * 0.4360.16 0.4960.31 * 0.2960.28 1.560.32
BP 1.1260.61 1.2360.49 1.8260.62 0.7860.21 0.5660.19 0.7460.25 0.3960.25 1.8160.42 *
NDUFS1 (75-kDa)
mRNA protein mRNA protein mRNA protein mRNA protein
Normal 1.2760.58 2.6360.52 0.8260.19 1.4060.13 1.1760.69 1.0860.19 ND ND
SCH 0.5560.16 * 2.6160.33 0.7360.50 1.0460.34 1.1460.32 1.0160.13 ND ND
MD 1.4560.55 2.8560.50 0.5260.25* 0.9560.29* 1.3060.65 0.9460.15 ND ND
BP 1.0960.56 2.2060.27 * 0.6260.14 0.9760.23 * 0.9260.54 0.9860.19 ND ND
Results are Mean6SD of arbitrary standardized densitometry values. *p,0.05 compared to control. MD-major depression, BP-bipolar, SCH- schizophrenic. (The data of
the prefrontal and parieto-occipital cortices are calculated from the data published in Karry et al. 2002).
doi:10.1371/journal.pone.0003676.t008
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differ in 51-kDa and 24-kDa subunits but differed significantly in the
75-kDa subunit (p=0.000).
Complex I subunits in the cerebellum
The lateral cerebellar hemisphere, which was planned to serve as
a control area, showed interesting significant inter-group differences
in mRNA of complex I subunits (NDUFV1-F(3,56)=23.780, p=
0.0001, NDUFV2-F(3,56)=12.234, p=0.0001 and NDUFS1-
F(3,56)=4.331, p=0.008). These changes were primarily due to
the decrease in NDUFV1 (57%, p=0.014), NDUFV2 (47%,
p=0.003) and NDUFS1 (36%, p=0.038) in the depressed group
as compared to controls, with less pronounced, but still significant,
changes in the bipolar group in NDUFV1 (57%, p=0.001) and
NDUFS1 (30%), which did not reach significance (Fig 4). Unlike the
findingsin striatum,the schizophrenicgroup didnotshow significant
changes from control in any of the three subunits. However, a
significant difference was observed between the schizophrenic group
and both groups with mood disorders.(NDUFV1, p=0.000 vs. both
bipolar and depressed; NDUFV2, p=0.000 vs. depressed). No
significant difference was observed between the depressed and the
bipolar groups.
Protein levels showed a parallel pattern of change to that of
mRNA in the lateral cerebellar hemisphere (51-kDa-F(3,56)=
13.833, p=0.0001; 24-kDa-F(3,56)=8.044, p=0.0001; 75-kDa-
F(3,56)=4.331, p=0.008) (Fig 5). Thus, a significant decrease in
the levels of the 51-kDa (43%, p=0.001) and 75-kDa (30% p=
0.024) subunits was observed in the bipolar group and of 51-, 24-
and 75-kDa subunits (49%, p=0.0001, 45%, p=0.001, 32%
p=0.014, respectively) in the depressed group. The schizophrenic
group showed no significant difference from the control group in
any of the subunits, similar to its mRNA findings, but was
significantly different from the depressed group (51-kDa,
p=0.015; 24-kDa, p=0.001). No significant difference was
observed between the bipolar group and both the depressed or
the schizophrenic group.
Demographic parameters, covariance analysis
To control for potential confounds, age, gender, PMI, brain pH,
side of brain, duration of disease, age of onset, severity of alcohol
and drug abuse and psychotropic medication were added as
covariates, and assessed by ANCOVA for all three subunits in the
striatum and in the cerebellum. Severity of alcohol and drug abuse
was scored from 0-no use to 6-heavy use. Disease related
significant differences, observed in mRNA and protein levels of
51-, 24- or 75-kDa subunits, were not altered by any of the
parameters used as covariant in all groups, including pH, alcohol
and drug abuse and lifetime antipsychotic dose, in both brain areas
for all patient groups, except for protein and mRNA levels of the
75-kDa, in which onset and duration of illness obliterated the
disease related significance, but showed no significant correlation
with 75-kDa mRNA or protein levels in any patient group. Table 8
presents disease-related adjusted means6SD of mRNA and
protein after ANCOVA, for all three genes in the four cohorts.
Figure 2. mRNA levels of NDUFV1, NDUFV2 and NDUFS1 subunits of complex I in post mortem striatum including the nucleus
accumbens of patients with schizophrenia (SCH, n=15), major depression (MD, n=15) and bipolar disorder (BP, n=15), and of
normal controls (n=15). Statistical significant differences vs. the control group were observed only in the schizophrenic group in all three subunits
of complex I.
doi:10.1371/journal.pone.0003676.g002
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Given the reported effects of antipsychotic drugs on brain
energy metabolism in motor areas, specifically in the basal ganglia
[42–44], together with their inhibitory effect on complex I activity
[30,33,45], we redefined our group variable to define 2 subgroups;
schizophrenic or bipolar patients medicated (12 schizophrenic, 7
bipolar patients) and unmedicated ( 3 schizophrenic, 8 bipolar
patients) with antipsychotic drugs. Three schizophrenic patients
and 3 bipolar patients were medication free and the other 5
bipolar patients received other psychotrophic drugs. No significant
difference was observed between the two subgroups in mRNA or
protein levels of all three subunits in the striatum and the
cerebellum. In addition, there was no significant correlation
between antipsychotic dose, expressed in fluphenazine milligram
equivalents, and mRNA or protein of any of the three subunits in
the antipsychotic medicated patients.
Effect of antidepressant medication
To asses possible effects of antidepressant medications on
complex I subunits in depressed subjects, we divided the depressed
group into 2 subgroups: subjects medicated with antidepressant
drugs (n=9) and unmedicated (n=6) subjects (two of them treated
with other psychotropic drugs). No significant difference between
groups was observed in mRNA or protein levels of all three
subunits in the two brain areas.
Effect of mood stabilizers
It was recently reported that lithium can affect genes of the
mitochondrial OXPHOS [46]. To asses possible effects of mood-
stabilizers on complex I subunits, we divided the bipolar group
into 2 subgroups: subjects medicated with mood-stabilizers (n=10)
and umedicated (n=5) subjects, 2 of them treated with other
psychotropic drugs. No significant difference was observed
between the two subgroups in mRNA or protein of all three
subunits in both brain areas. We then redefined our group variable
to include 2 subgroups: subjects receiving mood-stabilizers (n=16;
10 bipolar, 3 depressed, 3 schizophrenics) and subjects not
receiving mood-stabilizers (n=44), again there was no significant
difference between groups in both mRNA and protein of all three
subunits in the two brain areas.
Discussion
This study compares mRNA and protein levels of three subunits
of mitochondrial complex I in different brain areas of schizo-
phrenic, bipolar and depressed patients and normal subjects. The
main finding of the present study is that complex I subunits are
altered in all three psychiatric disorders, albeit in a disease specific
neuroanatomical pattern. In schizophrenia, but not in affective
disorders, a selective reduction in the 51- and 24-kDa subunit
expression was observed in the striatum. However, in both
affective disorders, reductions in complex I subunits were observed
Figure 3. Protein levels of 51-, 24-and 75-kDa subunits of complex I in post mortem striatum including the nucleus accumbens of
patients with schizophrenia (SCH, n=15), major depression (MD, n=15) and bipolar disorder (BP, n=15) and of normal controls
(n=15). Statistical significant differences vs. the control group were observed in the 51- and 24-kDa subunits of the schizophrenic group and in the
75-kDa subunit of the bipolar group. No statistically significant difference was observed in the depressed group.
doi:10.1371/journal.pone.0003676.g003
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strating more consistent alterations. Thus, the depressed patients
showed significant reductions in mRNA and protein of all three
subunits of complex I, while in the bipolar group mRNA and
protein of the 24-kDa subunit and only protein levels of the 75-
kDa subunit were reduced, with no significant changes in the 51-
kDa subunit. The phenomenon of a disease-specific regional
distribution of aberrant expression of complex I subunits was also
observed in our previous study on the same subject cohorts [26],
demonstrating a schizophrenia-specific reduction in the 51- and
24-kDa expression in the prefrontal cortex (BA 46/9). In the
parieto-occipital cortex (BA19), however, an increased expression
of these subunits was observed both in schizophrenic and bipolar
patients. In the depressed group, no consistent change was
observed in both brain areas. Interestingly, similar to schizophre-
nia, the bipolar group demonstrated some abnormality in the
striatum, as the 75-kDa protein levels were decreased in this area.
Taken together, the results of both studies indicate that while the
schizophrenic and depressed groups display disparate regional
distribution of complex I alterations, the bipolar group shares
considerable similarities with both the schizophrenic and de-
pressed groups. The latter is in line with the significant overlap
among patients with bipolar disorder and patients with schizo-
phrenia or major depression in clinical symptoms, neurocognitive
dysfunction, cerebral metabolism abnormalities, as well as brain
biochemical and molecular pathophysiological processes [47–50].
Psychotropic medication can conceivably contribute to disease-
specific regional alterations in complex I, as well as to the
anatomical overlap the bipolar group displays with both the
schizophrenic and depressed group. Indeed, it is well established
that antipsychotics, typical and atypical, interact with the
mitochondrial OXPHOS, specifically with complex I, directly
inhibiting its activity, both in vitro and in vivo in rodents and humans
[29,30,33,51]. In addition, mitochondria are a target for mood
stabilizers such as lithium and valproate [52] and for antidepres-
sant drugs [53], primarily MAO inhibitors. In the present study,
however, we were unable to detect any effect of antipsychotic,
antidepressant or mood stabilizing medication on the disorder-
related differences in mRNA or protein levels of complex I
subunits. Moreover, no differential effect on complex I subunits
could be observed upon dividing patients according to the type of
medication they were receiving at time of death. Although these
results should be taken with caution due to small sample size, this
lack of effect of antipsychotic drugs is in line with our previous
finding in platelets of schizophrenic patients [27], which suggests
that while complex I activity is affected by antipsychotic
medication, its subunits’ mRNA and protein expression is not, a
finding recently corroborated by our recent findings in the
neonatal ventral hippocampus lesion rat model of schizophrenia
[54] and unpublished data in neuronal cell line.
Another extensively addressed confounding factor in postmor-
tem brain studies is sample pH [36,55,56]. Although the
Figure 4. Cerebellar lateral hemisphere mRNA expression of complex I subunits. mRNA levels of NDUFV1, NDUFV2 and NDUFS1 subunits
of complex I in post mortem cerebellar lateral hemisphere of patients with schizophrenia (SCH, n=15), major depression (MD, n=15) and bipolar
disorder (BP, n=15), and of normal controls (n=15). Statistical significant differences vs. the control group were observed in all three subunits in the
major depression group and in the NDUFV1 in the bipolar group. No statistically significant difference was observed in the schizophrenic group.
doi:10.1371/journal.pone.0003676.g004
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it has been reported that the expression pattern of some genes
differs between low and high pH-brain specimens [36,55].
However, adding pH as a covariate did not change disease-related
effects on complex I, which is in line with our previous study [26]
and with its lack of effect on other genes such as glucocorticoid
receptor, cytosolic protein kinase Ce and kainate receptor 2 [57].
Other covariates such as age, gender, alcohol and drug abuse,
laterality and PMI had no effect on the statistical significance of
the differences between the diagnostic groups. These results, with
the reservation that small sample size may contribute to lack of
confounders’ effect, minimize the potential effect of possible
artifacts due to postmortem analysis, giving further credence to
disease-dependent main effects.
The present study examined three nuclear DNA encoded
subunits of complex I, the 51- and 24-kDa subunits, two iron-
sulfur flavoproteins with catalytic properties including the site for
transhydrogenation from NADH to NAD
+, and the 75-kDa, the
largest iron-sulfur transmembranous subunit [58]. All three
subunits form one functional subunit with a stoichiometry of
1mol of each subunit for 1mol of complex [59]. Therefore, it is
plausible that any deviation from this ratio can lead to abnormal
complex I activity. Indeed, we have previously shown that
abnormal expression of both the 51- and 24-kDa with no change
in the 75-kDa subunit, were associated with impaired activity of
complex I in platelets of schizophrenic patients [27]. Since
complex I activity measurement in whole tissue has low sensitivity
and postmortem delay significantly affects it [60], direct
assessment of brain complex I activity is relatively scarce. Taken
together, the data suggest that complex I subunits’ expression may
reflect abnormalities in complex I activity.
In schizophrenic patients we observed a decrease in complex I
subunits in prefrontal cortex and striatum, key elements in the
cortico–striatal-thalamic circuitry modulating cognitive processes
prominent in schizophrenia [61], and critically important in
biological processes believed to underlie psychotic symptoms
[62,63]. Congruently, most imaging studies report abnormal
metabolic activity of the cortico–striatal-thalamic circuitry in
schizophrenia [63]. In the parieto-occipital cortex, however,
increased levels of complex I subunits have been observed in
both schizophrenic and bipolar patients, in line with previous
findings of increased brain metabolic rates in both disorders [64].
The parieto-occipital cortex was shown to be involved in cognitive
processes of mental visual imagery [65]. Aberrations in the ability
to distinguish between perception and mental imagery has been
suggested to be associated with psychotic hallucinations and
paranoid delusions, characteristic of both disorders [66–68].
Interestingly, in the depressed group, alterations in both prefrontal
and parieto-occipital cortices were either sporadic or not expressed
at the functional relevant (protein) level.
Figure 5. Cerebellar lateral hemisphere protein expression of complex I subunits. Protein levels of the 51-, 24-and 75-kDa subunits of
complex I in post mortem Cerebellar lateral hemisphere of patients with schizophrenia (SCH, n=15), major depression (MD, n=15) and bipolar
disorder (BP, n=15), and of normal controls (n=15). Statistical significant differences vs. the control group were observed in all three subunits in the
major depression group and in the 51-kDa and the 75-kDa subunits in the bipolar group. No statistically significant difference was observed in the
schizophrenic group.
doi:10.1371/journal.pone.0003676.g005
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cerebellum as a prominent anatomical substrate for depression, as
most consistent alterations were observed in the depressed group but
also in the bipolar patients, as expected by the overlap of symptoms.
The role of the cerebellum has traditionally been limited to
coordination of voluntary movement, gait, posture, speech and
motor function. However, evidence from studies of patients with
overt cerebellar diseases as well as from normal subjects, suggests a
possible role for the cerebellum in cognition, mood and behavior
[69,70]. For example, cerebellar increase of blood flow is often seen
innormal subjects performing cognitive tasksand exposedto sadness
evoking challenges. Several studies have shown that patients with
various cerebellar pathologies demonstrate flattening of affect or
have higher depression scores than control subjects [70,71].
Furthermore, in patients with depression, transient mood challenges
produced less activation in the cerebellum, prefrontal and limbic
areas, than in healthy subjects [71–73]. Interestingly, it was reported
that refractory depression responded to treatment with a chronically
implanted cerebellar pacemaker [74]. In line with the suggested role
of the cerebellum in mood and behavior is the abundance of
serotonergic and noradrenergic inputs to the cerebellum, and their
ability to modulate the cerebellar circuitry and affect cerebellar
learning and control mechanisms [75].
The four brain areas we have analyzed are part of the neuronal
circuitries implicated in all three mental disorders. Structural and
functional imaging studies have implicated the cerebellum as part
of the cortico-thalamic-cerebellar-cortical circuit, in schizophrenia
[70,71]. In this study, however, complex I subunits expression was
unaltered in the lateral cerebellar hemisphere of the schizophrenic
group. Similarly, the prefrontal cortex has been implicated in
depression and in bipolar disorder, but alterations in complex I
were either sporadic or absent. This apparent contradiction may
be attributed to methodological differences, as imaging studies
usually sample a broader brain area and do not exclude circuit-
dependent inductions during measurement, whereas molecular
studies are more localized.
Finally, in the present and previous studies we have shown a
particular molecular pathology, in four discrete brain areas, and
detected disease-specific pattern of regional alterations. Given the
major role complex I plays in controlling mitochondrial OXPHOS
its abnormal activity can result in mitochondrial dysfunction.
Mitochondria, being the main source of high energy intermediates,
areofprominentimportanceinmaintainingthecellularenergystate,
particularly of high-energy consuming cells such as neurons. Hence,
we hypothesize that mitochondrial dysfunction and thereby
impaired neuronal metabolism can lead to alterations in neuronal
function, plasticity and brain circuitry. Mitochondrial dysfunction
can be either a causal ora consequential event of abnormal signaling
in specific brain circuitries. Previous studies utilizing pharmacolog-
ical tools to inhibit mitochondria, revealed defects in synaptic
potentiation and a failure to maintain neurotransmission under
rigorous stimulation [76,77]. Further evidence for the critical role of
mitochondria in neuronal activity is the finding that loss of
mitochondria from axon terminals result in defective synaptic
transmission in Drosophila [78–80] and that dendritic mitochondria
are essential in the morphogenesis and plasticity of spines and
synapses in hippocampal tissue slices [81,82]. Our findings of
mitochondrial impairment in peripheral blood cells in schizophrenia
may support the suggestion of mitochondrial dysfunction as a
primaryevent [24,27,83].However,anoppositeinteraction between
neuronal transmission and mitochondria was also demonstrated by
the ability of neurotransmitters, mainly glutamate but also
dopamine, to reciprocally affect mitochondrial function and ATP
production process in a cellular system as well as in-vivo [84–89].
Given this reciprocal interaction between both, the question of
primacy still remains an enigma.
Prefrontal cortex, parieto-occipital cortex, striatum and cere-
bellum may constitute one, or part of several complex neuronal
circuits critical for optimal functioning of normal cognition,
emotion and behavior. Considering our data as well as previously
reported data such as those on the differential anatomical
apolipoprotein D (apoD) abnormalities in schizophrenia and
bipolar disorder [90], it is tempting to suggest that the diversity in
the clinical spectrum of mental disorders may, at least in part, be
attributed to the different anatomical pattern of specific impair-
ments in the neuronal circuits implicated in the disorders.
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